These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 15357776

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM, RAHF-PFM Clinical Study Group.
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [Abstract] [Full Text] [Related]

  • 6. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M, Cortesi PA, Steinitz-Trost KN, Reininger AJ, Gringeri A, Mantovani LG.
    Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
    [Abstract] [Full Text] [Related]

  • 9. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.
    Aledort LM, Navickis RJ, Wilkes MM.
    J Thromb Haemost; 2011 Nov; 9(11):2180-92. PubMed ID: 21848690
    [Abstract] [Full Text] [Related]

  • 10. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M.
    Blood; 1994 May 01; 83(9):2428-35. PubMed ID: 8167332
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S, Cannavò A, Gouw SC, Rosendaal FR, van der Bom JG.
    J Thromb Haemost; 2018 Jun 01; 16(6):1055-1068. PubMed ID: 29665204
    [Abstract] [Full Text] [Related]

  • 13. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L, Kavakli K, Korth-Bradley J, Huard F, Rendo P, Fuiman J, Baumann JA, Smith L, Alvey C, Rupon J.
    Haemophilia; 2018 Jul 01; 24(4):604-610. PubMed ID: 29582525
    [Abstract] [Full Text] [Related]

  • 14. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA, Evans MA, Skaer TL, Robison LM, Chung KC, Poulios NS.
    Drugs R D; 2005 Jul 01; 6(3):149-56. PubMed ID: 15869318
    [Abstract] [Full Text] [Related]

  • 15. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B.
    Thromb Haemost; 2012 Jun 01; 107(6):1072-82. PubMed ID: 22476554
    [Abstract] [Full Text] [Related]

  • 16. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC, Courter S, Bray GL, Lee M, Gomperts ED.
    Thromb Haemost; 1997 Apr 01; 77(4):660-7. PubMed ID: 9134639
    [Abstract] [Full Text] [Related]

  • 17. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M, EUHASS participants.
    Thromb Haemost; 2015 May 01; 113(5):968-75. PubMed ID: 25567324
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.
    Haemophilia; 2019 May 01; 25(3):398-407. PubMed ID: 31066174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.